Quinacrine Disease Interactions
There are 4 disease interactions with quinacrine.
Aminoquinolines (applies to quinacrine) porphyria
Major Potential Hazard, Moderate plausibility.
The use of aminoquinolines in patients with porphyria may exacerbate the condition. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.
Aminoquinolines (applies to quinacrine) glucose-6-PD deficiency
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: G-6-PD Deficiency
Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Therapy with aminoquinolines should be administered cautiously in these patients. Blood cell counts and hemoglobin determinations should be performed regularly. Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.
Aminoquinolines (applies to quinacrine) hepatotoxicity
Moderate Potential Hazard, Low plausibility. Applicable conditions: Liver Disease, Alcoholism
Aminoquinolines may concentrate in the liver. Isolated cases of abnormal liver function and fulminant hepatic failure have been reported. Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs. Periodic evaluation of hepatic function should be performed during prolonged therapy.
Aminoquinolines (applies to quinacrine) psoriasis
Moderate Potential Hazard, Moderate plausibility.
The use of aminoquinolines in patients with psoriasis may precipitate a severe attack of psoriasis. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.
Switch to professional interaction data
Quinacrine drug interactions
There are 13 drug interactions with quinacrine.
Report options
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Arakoda
Arakoda is used for the treatment of Plasmodium vivax malaria. Arakoda information includes news ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Plaquenil
Plaquenil is used to treat or prevent malaria and to treat the symptoms of rheumatoid arthritis ...
Tafenoquine
Tafenoquine systemic is used for malaria, malaria prevention
Quinine
Quinine systemic is used for malaria, myotonia congenita, nocturnal leg cramps
Primaquine
Primaquine systemic is used for malaria, malaria prevention, pneumocystis pneumonia
Hydroxychloroquine
Hydroxychloroquine is a quinoline drug used to treat or prevent malaria. It's also used to treat ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.